The NDA submissions are for 2 formulations of crinecerfont: a capsule and an oral solution. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Applications (NDA) for ...

SAN FRANCISCO -- Crinecerfont (Crenessity) may help improve metabolic profiles of adults and children with classic congenital adrenal hyperplasia (CAH), analyses of phase III CAHtalyst trial data ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved crinecerfont to treat patients with congenital adrenal hyperplasia. The drug directly reduces ...

SAN DIEGO, May 15, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from the Phase 3 CAHtalyst™ Adult and Pediatric studies of CRENESSITY™ (crinecerfont). The ...

One-year data from CAHtalyst ™ Adult study demonstrated lasting reductions in glucocorticoid dose and improvement in clinical outcomes in adults with classic congenital adrenal hyperplasia Results ...

In adults, open-label data showed a sustained steroid-reducing benefit with the oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist, according to findings presented by Sonal Vaid, MD ...

Credit: Shutterstock. Crinecerfort is an investigational, oral, selective corticotropin-releasing factor type 1 receptor (CRF1) antagonist. A phase 3 study evaluating the efficacy and safety of ...

Neurocrine Biosciences needs a clinical win after years of disappointing results and stagnant stock performance. The upcoming Phase III data on crinecerfont, a treatment for congenital adrenal ...

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) Monday announced data from its completed Phase II study of crinecerfont (NBI-74788). The company said the study showed meaningful reductions in all ...

Please provide your email address to receive an email when new articles are posted on . An investigational nonsteroidal treatment for classic congenital adrenal hyperplasia improved levels of ...

Neurocrine Biosciences has reported very positive Phase III results for crinecerfont in adult and pediatric congenital adrenal hyperplasia. The adult study showed that 63% of patients on crinecerfont ...